Aurora Cannabis Inc. (ACB) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Aurora Cannabis Inc. (ACB) Healthcare & Pipeline Overview

Aurora Cannabis Inc. is a global cannabis company focused on producing and distributing a diverse portfolio of cannabis and derivative products. Operating in the specialty and generic drug manufacturing industry, Aurora distinguishes itself through facility engineering, cannabis breeding programs, and robust research and product development initiatives.

What Is the Investment Thesis for ACB?

Aurora Cannabis Inc. presents a speculative investment opportunity within the evolving cannabis market. Key value drivers include the expansion of its product lines and penetration into new international markets. The company's focus on research and development may lead to innovative products that capture a larger market share. However, potential investors may want to evaluate the risks associated with regulatory uncertainties, intense competition, and the company's history of negative profit margins, currently at -11.7%. Successful execution of strategic initiatives and achieving profitability are critical for long-term value creation. The company's beta of 1.30 indicates higher volatility compared to the market.

Based on FMP financials and quantitative analysis

ACB Key Highlights

Aurora Cannabis Inc. operates with a workforce of 1073 employees, reflecting its scale of operations in the cannabis industry.

• The company's market capitalization stands at $231M as of May 9, 2026, indicating its current valuation in the market.
• Aurora Cannabis Inc. reports a negative profit margin of -11.7%, highlighting ongoing challenges in achieving profitability.
• The company boasts a gross margin of 49.5%, showcasing its ability to generate revenue above the cost of goods sold.
• Aurora Cannabis Inc. does not currently offer a dividend, which is common among growth-oriented companies in the cannabis sector.

Who Are ACB's Competitors?

ACB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ACB's Key Strengths?

Diverse product portfolio catering to both medical and recreational markets.

• Established brand recognition with brands like Aurora and San Rafael '71.
• Significant production capacity with advanced cultivation facilities.
• Focus on research and development for innovative cannabis products.

What Are ACB's Weaknesses?

History of negative profit margins and financial losses.

• High operating expenses and cost structure.
• Exposure to regulatory uncertainties and market volatility.
• Dependence on the Canadian market for a significant portion of revenue.

What Could Drive ACB Stock Higher?

Potential regulatory changes in key international markets could open new opportunities for Aurora's expansion.

• Continued growth in the medical cannabis market driven by increasing acceptance and research.
• Launch of new and innovative cannabis products, including edibles and beverages, to attract new customer segments.
• Strategic partnerships and acquisitions to expand market reach and enhance product offerings.

What Are the Key Risks for ACB?

Financial-distress signal — its Altman Z-Score of -11.75 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-7.8%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Intense competition from other cannabis producers, both established players and new entrants.
• Evolving regulations and potential restrictions on cannabis sales and marketing.
• Price volatility and fluctuations in cannabis demand due to market dynamics.
• Dependence on the Canadian market for a significant portion of revenue, exposing the company to regional risks.
• Delays in regulatory approvals and market access in international markets.

What Are the Growth Opportunities for ACB?

• Expansion into International Markets: Aurora Cannabis has the opportunity to expand its presence in international markets, particularly in Europe and Latin America, where cannabis regulations are becoming more favorable. The global cannabis market is projected to reach $55.91 billion by 2030, presenting a significant growth opportunity for Aurora. Successful market entry and strategic partnerships could drive revenue growth and increase market share. The timeline for realizing these benefits depends on regulatory approvals and market dynamics.
• Development of Innovative Products: Investing in research and development to create innovative cannabis products, such as edibles, beverages, and wellness products, can attract new customer segments and increase revenue. The market for cannabis-infused products is growing rapidly, driven by consumer demand for alternative consumption methods. Aurora's focus on product innovation can differentiate it from competitors and drive long-term growth. This includes the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products.
• Strategic Partnerships and Acquisitions: Forming strategic partnerships with established companies in related industries, such as pharmaceuticals or consumer goods, can provide access to new markets, technologies, and distribution channels. Acquisitions of smaller cannabis companies with unique product offerings or regional presence can also accelerate growth. These partnerships can enhance Aurora's competitive position and drive revenue synergies. The timeline for realizing these benefits depends on the successful integration of acquired assets and the execution of partnership agreements.
• Focus on Medical Cannabis Market: Concentrating on the medical cannabis market, which offers higher margins and less regulatory uncertainty compared to the recreational market, can improve profitability and reduce risk. Developing targeted therapies for specific medical conditions and building relationships with healthcare professionals can drive demand for Aurora's medical cannabis products. The medical cannabis market is expected to continue growing as research validates the therapeutic benefits of cannabis. This includes operation of CanvasRX, a network of cannabis counseling and outreach centers.
• Cost Optimization and Efficiency Improvements: Implementing cost optimization measures and improving operational efficiency can enhance profitability and free up resources for investment in growth initiatives. This includes streamlining production processes, reducing overhead costs, and optimizing supply chain management. Aurora's ability to control costs and improve efficiency will be critical for achieving sustainable profitability and competing effectively in the cannabis market. The company can also focus on facility engineering and design to improve efficiency.

What Are ACB's Competitive Advantages?

• Brand Portfolio: Aurora's diverse brand portfolio, including Aurora, Aurora Drift, and San Rafael '71, provides a competitive advantage.
• Production Capacity: The company's large-scale production facilities enable it to meet growing demand for cannabis products.
• Research and Development: Aurora's investment in research and development allows it to create innovative and differentiated products.
• Distribution Network: The company's established distribution network provides access to key markets and customers.

What Does ACB Do?

Aurora Cannabis Inc., headquartered in Edmonton, Canada, cultivates, distributes, and sells cannabis and cannabis derivative products both domestically and internationally. The company's operations span the entire cannabis value chain, from facility engineering and design to cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution. Aurora produces various strains of dried cannabis, cannabis oil, and capsules, as well as topical kits tailored for medical patients. The company also offers vaporizers, consumable vaporizer accessories, and herb mills designed for use with CanniMed herbal cannabis products, alongside grinders and vaporizer lockable containers. Aurora's commitment to innovation is evident in its ongoing development of medical cannabis products, including oral, topical, edible, and inhalable formulations. The company also operates CanvasRX, a network of cannabis counseling and outreach centers. Aurora provides patient counseling services, design and construction services, and cannabis analytical product testing services. Its diverse brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. Aurora continues to evolve its product offerings and expand its market presence within the global cannabis industry.

What Products and Services Does ACB Offer?

• Produces various strains of dried cannabis for medical and recreational use.
• Manufactures cannabis oil and capsules for medical patients.
• Develops and sells topical kits for localized relief.
• Offers vaporizers and consumable accessories for cannabis consumption.
• Engages in facility engineering and design for cannabis cultivation.
• Conducts cannabis breeding and research to develop new strains.
• Provides wholesale and retail distribution of cannabis products.
• Develops medical cannabis products, including oral, topical, edible, and inhalable formulations.

How Does ACB Make Money?

• Cultivation and Production: Aurora cultivates and produces cannabis at its facilities, ensuring a consistent supply of raw materials.
• Product Manufacturing: The company manufactures a range of cannabis products, including dried flower, oils, capsules, and edibles.
• Distribution and Sales: Aurora distributes its products through wholesale channels, retail stores, and online platforms.
• Research and Development: The company invests in research and development to create new and innovative cannabis products.

What Industry Does ACB Operate In?

Aurora Cannabis Inc. operates within the rapidly evolving cannabis industry, which is experiencing significant growth and regulatory changes globally. The market is characterized by increasing demand for both medical and recreational cannabis products. Aurora competes with other major cannabis producers, including Canopy Growth Corporation and Tilray, as well as numerous smaller players. The industry is subject to evolving regulations, which can impact market access and profitability. Companies that can navigate these regulatory hurdles and establish strong brands are positioned for success.

Who Are ACB's Key Customers?

• Medical Patients: Individuals seeking cannabis-based treatments for various medical conditions.
• Recreational Consumers: Adults who use cannabis for personal enjoyment and relaxation.
• Wholesale Distributors: Companies that purchase cannabis products in bulk for resale to retailers.
• Retail Partners: Retail stores and dispensaries that sell Aurora's products directly to consumers.

Company Profile

Aurora Cannabis Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Edmonton, CA. The company is led by CEO Miguel Martin. ACB has traded publicly since 2014.

Aurora Cannabis Inc. Financial Trajectory

Aurora Cannabis Inc. (ACB) reported $48.7M in revenue for Jun 2026, reflecting 77.3% growth compared to the prior quarter. The company recorded a net loss of $2.9M, with diluted EPS of $-0.05. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ACB averaged $-0.35 in diluted EPS.

How Aurora Cannabis Inc. Is Valued

Aurora Cannabis Inc. carries a market capitalization of $231M, placing it in the micro-cap category. Relative to its peer group, ACB's quantitative score of 18/100 is below the peer average of 49/100.

Return on equity for Aurora Cannabis Inc. stands at -7.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -11.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.06 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -15.1%, the inverse of the P/E and a quick read on earnings relative to price.

Aurora Cannabis Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -11.75 places it in the distress zone, a signal of elevated financial risk.

Aurora Cannabis Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 1010.0% above estimates on average.

Wall Street analysts project Aurora Cannabis Inc. revenue of about $359.3M for fiscal 2026, with EPS near $-1.20. The estimate reflects 4 contributing analysts.

ACB Financials

ACB Latest News

ACB Analyst Consensus

ACB MoonshotScore

ACB Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources